NR4A1 and breast carcinoma: showed that a high ratio of extranuclear-to-nuclear estrogen receptor alpha (ERα) in patients with hormone receptor-positive and HER2-negative breast cancer indicates a decreased likelihood of benefiting from hormone therapy (30).